| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Department Physiology (M.F., F.A.R., X.X., A.L., T.H.H.), New York Medical College, Valhalla, NY; and the Molecular Medicine Laboratory (N.A., L.Z., S.Z., M.G.), International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.
Correspondence to Thomas H. Hintze PhD, Professor, Department of Physiology, New York Medical College, Valhalla, NY 10595. E-mail Thomas_Hintze{at}NYMC.edu
We have previously shown that VEGF165 gene delivery into ischemic skeletal muscle exerts not only proangiogenic, but also remarkable antiapoptotic and proregenerative activity. The aim of this study was to determine whether recombinant adeno-associated virus (rAAV)-mediated gene delivery of VEGF165 into cardiac muscle, during acute myocardial infarction, exerts a protective effect to promote long-term functional recovery. Acute infarction of the anterior LV wall was induced in 12 chronically instrumented dogs by permanent occlusion of the LAD coronary artery. Four hours after occlusion, rAAV-VEGF165 or rAAV-LacZ (n=6 each; 5x1012 viral particles per animal) was directly injected with an echo-guided needle into the dysfunctional cardiac wall. LV and arterial pressure, dP/dtmax, and ejection fraction were not significantly different between the two groups over time. In contrast, in the infarcted region, at four weeks after infarction, fractional shortening was 75±18% and 3±15% of baseline and length-pressure area was 54±15% and 0.8±15% of baseline in VEGF165 versus LacZ, respectively (P<0.05). Histological analysis of the border regions showed a marked increase in the number of
-SMA-positive arterioles (68±2.8 versus 100±3.8 vessels per microscopic field in LacZ and VEGF165 group, respectively; P<0.05). In both groups, the receptor VEGFR-2 was diffusely expressed on the surviving cardiomyocytes and, consistently, myocardial viability was significantly improved in the VEGF165-treated group, with several troponin T-expressing cardiomyocytes displaying nuclear positivity for the proliferation marker PCNA. Altogether, our results indicate that VEGF165 gene delivery exerts a marked beneficial action by enhancing both arteriologenesis and cardiomyocyte viability in infarcted myocardium.
Key Words: VEGF receptors angiogenesis myocardial infarction cardiac regeneration gene therapy AAV vectors
This article has been cited by other articles:
![]() |
S. Tafuro, E. Ayuso, S. Zacchigna, L. Zentilin, S. Moimas, F. Dore, and M. Giacca Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression Cardiovasc Res, September 1, 2009; 83(4): 663 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, L. Ding, Y. Zhao, W. Sun, B. Chen, H. Lin, X. Wang, L. Zhang, B. Xu, and J. Dai Collagen-Targeting Vascular Endothelial Growth Factor Improves Cardiac Performance After Myocardial Infarction Circulation, April 7, 2009; 119(13): 1776 - 1784. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saeed, A. Martin, A. Jacquier, M. Bucknor, D. Saloner, L. Do, P. Ursell, H. Su, Y. W. Kan, and C. B. Higgins Permanent Coronary Artery Occlusion: Cardiovascular MR Imaging Is Platform for Percutaneous Transendocardial Delivery and Assessment of Gene Therapy in Canine Model Radiology, November 1, 2008; 249(2): 560 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carlsson, N. F. Osman, P. C. Ursell, A. J. Martin, and M. Saeed Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H522 - H532. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Saxena, J. E. Fish, M. D. White, S. Yu, J. W.P. Smyth, R. M. Shaw, J. M. DiMaio, and D. Srivastava Stromal Cell-Derived Factor-1{alpha} Is Cardioprotective After Myocardial Infarction Circulation, April 29, 2008; 117(17): 2224 - 2231. [Abstract] [Full Text] [PDF] |
||||
![]() |
A R Lyon, M Sato, R J Hajjar, R J Samulski, and S E Harding Gene therapy: targeting the myocardium Heart, January 1, 2008; 94(1): 89 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Unger How Can Cardiac MR Imaging Help Guide Development of Gene Therapy for Treatment of Coronary Heart Disease? Radiology, October 1, 2007; 245(1): 1 - 2. [Full Text] [PDF] |
||||
![]() |
A. Jacquier, C. B. Higgins, A. J. Martin, L. Do, D. Saloner, and M. Saeed Injection of Adeno-associated Viral Vector Encoding Vascular Endothelial Growth Factor Gene in Infarcted Swine Myocardium: MR Measurements of Left Ventricular Function and Strain Radiology, October 1, 2007; 245(1): 196 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saeed, D. Saloner, A. Martin, L. Do, O. Weber, P. C. Ursell, A. Jacquier, R. Lee, and C. B. Higgins Adeno-associated Viral Vector-Encoding Vascular Endothelial Growth Factor Gene: Effect on Cardiovascular MR Perfusion and Infarct Resorption Measurements in Swine Radiology, May 1, 2007; 243(2): 451 - 460. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Crottogini and R. Laguens Letter to the Editor: VEGF165 Gene-Mediated Arteriogenesis and Cardioprotection in Large Mammals With Acute Myocardial Infarction. Confirmation of Previous Results From Other Authors Circ. Res., March 2, 2007; 100(4): e58 - e58. [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |